PHARMACEUTICAL 2015

Ayala Pharmaceuticals Inc
Rank 108 of 274

ADVAXIS IMMUNOTHERAPIES™



PHARMACEUTICAL 2015

Ayala Pharmaceuticals Inc
Rank 108 of 274

The relative strengths and weaknesses of Ayala Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ayala Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 99% points.The greatest weakness of Ayala Pharmaceuticals Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 314%, being 60% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	20,494
Cost of Goods Sold	0
Intangible Assets	2,768
Liabilities, Current	2,716
Liabilities, Non-Current	0
Other Assets	38
Other Compr. Net Income	0
Other Expenses	-2,352
Other Liabilities	32
Other Net Income	662
Other Revenues	1,000
Property and Equipment	77
Research and Development	8,687
Selling, General and Administrative Expense	11,851

Output Variable	Value in 1000 USD
Assets	23,378
Liabilities	2,748
Expenses	18,187
Revenues	1,000
Stockholders Equity	20,630
Net Income	-16,525
Comprehensive Net Income	-16,525
BaseVar	22,987
ECR before LimitedLiability	218%
Economic Capital Ratio	314%